138 related articles for article (PubMed ID: 9835904)
21. Cardiac safety profile of prolonged (>or=6 cycles) pegylated liposomal doxorubicin administration in patients with gynecologic malignancies.
Uyar D; Kulp B; Peterson G; Zanotti K; Markman M; Belinson J
Gynecol Oncol; 2004 Jul; 94(1):147-51. PubMed ID: 15262133
[TBL] [Abstract][Full Text] [Related]
22. Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies.
Chow WA; Synold TW; Tetef ML; Longmate J; Frankel P; Lawrence J; Al-Khadimi Z; Leong L; Lim D; Margolin K; Morgan RJ; Raschko J; Shibata S; Somlo G; Twardowski P; Yen Y; Doroshow JH
Cancer Chemother Pharmacol; 2004 Sep; 54(3):241-8. PubMed ID: 15173955
[TBL] [Abstract][Full Text] [Related]
23. Cardiac troponin I: is it a marker to detect cardiotoxicity in children treated with doxorubicin?
Köseoğlu V; Berberoğlu S; Karademir S; Kismet E; Yurttutan N; Demirkaya E; Sungur M; Alehan D
Turk J Pediatr; 2005; 47(1):17-22. PubMed ID: 15884624
[TBL] [Abstract][Full Text] [Related]
24. Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer.
Lipshultz SE; Lipsitz SR; Mone SM; Goorin AM; Sallan SE; Sanders SP; Orav EJ; Gelber RD; Colan SD
N Engl J Med; 1995 Jun; 332(26):1738-43. PubMed ID: 7760889
[TBL] [Abstract][Full Text] [Related]
25. Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac Outcomes.
Lipshultz SE; Miller TL; Lipsitz SR; Neuberg DS; Dahlberg SE; Colan SD; Silverman LB; Henkel JM; Franco VI; Cushman LL; Asselin BL; Clavell LA; Athale U; Michon B; Laverdière C; Schorin MA; Larsen E; Usmani N; Sallan SE;
Pediatrics; 2012 Dec; 130(6):1003-11. PubMed ID: 23166343
[TBL] [Abstract][Full Text] [Related]
26. Doxorubicin and paclitaxel (sequential combination) in the treatment of advanced breast cancer.
Amadori D; Frassineti GL; Zoli W; Milandri C; Serra P; Tienghi A; Ravaioli A; Gentile A; Salzano E
Oncology (Williston Park); 1997 Apr; 11(4 Suppl 3):30-3. PubMed ID: 9144688
[TBL] [Abstract][Full Text] [Related]
27. Cardiotoxicity of doxorubicin/paclitaxel combination in rats: effect of sequence and timing of administration.
Saad SY; Najjar TA; Alashari M
J Biochem Mol Toxicol; 2004; 18(2):78-86. PubMed ID: 15122649
[TBL] [Abstract][Full Text] [Related]
28. Different anthracycline derivates for reducing cardiotoxicity in cancer patients.
van Dalen EC; Michiels EM; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2006 Oct; (4):CD005006. PubMed ID: 17054231
[TBL] [Abstract][Full Text] [Related]
29. A phase 1B/2 study of aldoxorubicin in patients with soft tissue sarcoma.
Chawla SP; Chua VS; Hendifar AF; Quon DV; Soman N; Sankhala KK; Wieland DS; Levitt DJ
Cancer; 2015 Feb; 121(4):570-9. PubMed ID: 25312684
[TBL] [Abstract][Full Text] [Related]
30. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy.
van Dalen EC; van der Pal HJ; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2006 Oct; (4):CD005008. PubMed ID: 17054232
[TBL] [Abstract][Full Text] [Related]
31. Serial Magnetic Resonance Imaging to Identify Early Stages of Anthracycline-Induced Cardiotoxicity.
Galán-Arriola C; Lobo M; Vílchez-Tschischke JP; López GJ; de Molina-Iracheta A; Pérez-Martínez C; Agüero J; Fernández-Jiménez R; Martín-García A; Oliver E; Villena-Gutierrez R; Pizarro G; Sánchez PL; Fuster V; Sánchez-González J; Ibanez B
J Am Coll Cardiol; 2019 Feb; 73(7):779-791. PubMed ID: 30784671
[TBL] [Abstract][Full Text] [Related]
32. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer.
Jain KK; Casper ES; Geller NL; Hakes TB; Kaufman RJ; Currie V; Schwartz W; Cassidy C; Petroni GR; Young CW
J Clin Oncol; 1985 Jun; 3(6):818-26. PubMed ID: 3859587
[TBL] [Abstract][Full Text] [Related]
33. 6-gingerol ameliorated doxorubicin-induced cardiotoxicity: role of nuclear factor kappa B and protein glycation.
El-Bakly WM; Louka ML; El-Halawany AM; Schaalan MF
Cancer Chemother Pharmacol; 2012 Dec; 70(6):833-41. PubMed ID: 23014738
[TBL] [Abstract][Full Text] [Related]
34. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
[TBL] [Abstract][Full Text] [Related]
35. Equivalence Ratio for Daunorubicin to Doxorubicin in Relation to Late Heart Failure in Survivors of Childhood Cancer.
Feijen EA; Leisenring WM; Stratton KL; Ness KK; van der Pal HJ; Caron HN; Armstrong GT; Green DM; Hudson MM; Oeffinger KC; Robison LL; Stovall M; Kremer LC; Chow EJ
J Clin Oncol; 2015 Nov; 33(32):3774-80. PubMed ID: 26304888
[TBL] [Abstract][Full Text] [Related]
36. Prospective evaluation of cardiotoxicity during a six-hour doxorubicin infusion regimen in women with adenocarcinoma of the breast.
Speyer JL; Green MD; Dubin N; Blum RH; Wernz JC; Roses D; Sanger J; Muggia FM
Am J Med; 1985 Apr; 78(4):555-63. PubMed ID: 3838618
[TBL] [Abstract][Full Text] [Related]
37. High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.
Morgan RJ; Doroshow JH; Venkataraman K; Chang K; Raschko J; Somlo G; Leong L; Tetef M; Shibata S; Hamasaki V; Margolin K; Forman S; Akman S; Coluzzi P; Ahn C; Weiss L; Gadgil U; Harrison J
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2337-45. PubMed ID: 9815632
[TBL] [Abstract][Full Text] [Related]
38. Revisiting the role of doxorubicin in the treatment of rhabdomyosarcoma: an up-front window study in newly diagnosed children with high-risk metastatic disease.
Bergeron C; Thiesse P; Rey A; Orbach D; Boutard P; Thomas C; Schmitt C; Scopinaro MJ; Bernard F; Stevens M; Oberlin O
Eur J Cancer; 2008 Feb; 44(3):427-31. PubMed ID: 18215514
[TBL] [Abstract][Full Text] [Related]
39. Oxidative stress on cardiotoxicity after treatment with single and multiple doses of doxorubicin.
Segredo MP; Salvadori DM; Rocha NS; Moretto FC; Correa CR; Camargo EA; de Almeida DC; Reis RA; Freire CM; Braz MG; Tang G; Matsubara LS; Matsubara BB; Yeum KJ; Ferreira AL
Hum Exp Toxicol; 2014 Jul; 33(7):748-60. PubMed ID: 24275640
[TBL] [Abstract][Full Text] [Related]
40. A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors.
Planting AS; Sonneveld P; van der Gaast A; Sparreboom A; van der Burg ME; Luyten GP; de Leeuw K; de Boer-Dennert M; Wissel PS; Jewell RC; Paul EM; Purvis NB; Verweij J
Cancer Chemother Pharmacol; 2005 Jan; 55(1):91-9. PubMed ID: 15565444
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
